NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- BrainStorm Cell Therapeutics Inc. (OTC Bulletin Board: BCLI), a leading developer of adult stem cell technologies and therapeutics, is excited and honored to state the appointment of Rasheda Ali, revered author and daughter of renowned boxer and long time Parkinson's sufferer Muhammad Ali, as a member of the company's Advisory Board. BrainStorm has announced results leading to a possible cure for Parkinson's, which drew the attention of philanthropist Ali, an advocate in finding a cure for her father's debilitating disease.

As the author of I'll Hold Your Hand So You Won't Fall - a Child's Guide to Parkinson's Disease her longtime goal has been to encourage a dialogue between parents and children. Continuing her efforts toward national and international awareness and pursuing medical breakthroughs for Parkinson's, she will now champion Brainstorm's research and advancements, in her new role.

'I am very excited to be part of the BrainStorm Advisory Board and focus more attention on spotlighting their groundbreaking research towards a cure for Parkinson's,' says Ali. 'This is obviously a very personal issue for me, as I continue to pray daily for a cure for my father, which it seems BrainStorm is determined to find. I cannot wait to lend a hand.'

'As a role model and a living example of how to cope with her own father's struggle with Parkinson's, Rasheda is a natural fit for our cause. We are very excited to have her collaborate with BrainStorm as a pivotal member of our Advisory Board, joining the ranks of notable world class business leaders like Prof. Jacob Frenkel and Harvey Krueger,' commented Chaim Lebovits, President. 'We know through her passion to find a cure for her father, she will continue to do great things for those who suffer from Parkinson's -- both family and patient.'

Leveraging her celebredom and humanitarian legacy, Rasheda wants to bring further awareness to the Parkinson's issue. Over 1 million Americans suffer from Parkinson's, with more victims, young and old, being diagnosed daily. 40% of victims are under the age of 60 and it is estimated that Parkinson's costs the U.S. over $26 billion annually in disability costs and lost productivity. Currently, there is no cure for Parkinson's though BrainStorm Cell Therapeutics is well on its way to conquering this horrible disease via adult stem cell research.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an early stage company engaged in developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's initial focus is on Parkinson's disease, although its technology may have promise for treating several other diseases including MS and Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute 'forward-looking statements' and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete the financings described in this press release and its ability to satisfy all of the closing conditions. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; limited cash resources and its need to raise additional capital to execute on its business plan and continue operations; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.

Contact: Alyssa Miller

(212) 584-4290; amiller@5wpr.com

SOURCE BrainStorm Cell Therapeutics Inc.

Source: PR Newswire (October 16, 2007 - 7:01 AM EDT)

News by QuoteMedia
www.quotemedia.com